Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : GNTI-122
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of GNTI-122 in Adults Recently Diagnosed With T1D
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 09, 2025
Lead Product(s) : GNTI-122
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Study Phase : Discovery Platform
Sponsor : Bristol Myers Squibb
Deal Size : $1,900.0 million
Deal Type : Collaboration
Details : GentiBio will apply its engineered regulatory T cell platform in a deal with BMS to develop new engineered Treg therapies to treat inflammatory bowel diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 08, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Highest Development Status : Discovery Platform
Sponsor : Bristol Myers Squibb
Deal Size : $1,900.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Matrix Capital Management
Deal Size : $157.0 million
Deal Type : Series A Financing
Details : Funding will advance novel pipeline of best-in-class engineered regulatory T cell therapies to durably restore immune tolerance and treat autoimmune, alloimmune, autoinflammatory, and allergic diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 08, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Matrix Capital Management
Deal Size : $157.0 million
Deal Type : Series A Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Preclinical
Recipient : Forge Biologics
Deal Size : Undisclosed
Deal Type : Agreement
GentiBio, Forge Biologics Ink Development and Manufacturing Agreement
Details : Under the terms of the agreement, Forge will provide adeno-associated viral (AAV) vector process and analytical development, scale-up engineering and GMP manufacturing services for GentiBio’s engineered Tregs therapeutic candidates.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 15, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Recipient : Forge Biologics
Deal Size : Undisclosed
Deal Type : Agreement